Cost–Utility Analysis of Palonosetron-Based Therapy in Preventing Emesis Among Breast Cancer Patients

This publication has 27 references indexed in Scilit:

• Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
  The Lancet Oncology, 2009
• Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy
  Supportive Care in Cancer, 2008
• American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
  Journal of Clinical Oncology, 2006
• Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy
  Journal of Clinical Oncology, 2005
• Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update
  Supportive Care in Cancer, 2004
• Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT₃ receptor antagonist
  Cancer, 2003
• Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
  Annals of Oncology, 2003
• Dexamethasone Alone or in Combination with Ondansetron for the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy
  New England Journal of Medicine, 2000
• Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
  British Journal of Cancer, 1997
• Dexamethasone, Granisetron, or Both for the Prevention of Nausea and Vomiting during Chemotherapy for Cancer
  New England Journal of Medicine, 1995